Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-a-pyrone (coumarin), and the effects of diethylcarbamazine (DEC)
Identifieur interne : 000D75 ( PascalFrancis/Curation ); précédent : 000D74; suivant : 000D76Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-a-pyrone (coumarin), and the effects of diethylcarbamazine (DEC)
Auteurs : J. R. Casley-Smith [Australie] ; S. Jamal ; J. R. Casley-SmithSource :
- Annals of tropical medicine and parasitology [ 0003-4983 ] ; 1993.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
Chronic filaritic lymphoedema and elephantiasis, in India, were treated orally with 5,6 benzo-a-pyrone (56 BaP; 1,2 benzo-a-pyrone; coumarin) in a double-blind, randomized, matched-group trial. Each group finally contained 40-55 patients. Patients were observed for about 2 years (ranging from 6 to 45 months, with 75% completing the 2 years). The 56 BaP slowly, but very significantly (P < 0.0001), reduced all grades of lymphoedema and elephantiasis. Two thirds of the oedema was lost by grade 2 over 2 years. Grades 3 to 5 were reduced by a fifth over that time. The greater the initial oedema, the greater was its rate of resolution
pA |
|
---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D33
Links to Exploration step
Pascal:93-0640187Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-a-pyrone (coumarin), and the effects of diethylcarbamazine (DEC)</title>
<author><name sortKey="Casley Smith, J R" sort="Casley Smith, J R" uniqKey="Casley Smith J" first="J. R." last="Casley-Smith">J. R. Casley-Smith</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Univ. Adelaide, Henry Thomas lab.</s1>
<s2>Adelaide SA 5001</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Jamal, S" sort="Jamal, S" uniqKey="Jamal S" first="S." last="Jamal">S. Jamal</name>
</author>
<author><name sortKey="Casley Smith, J R" sort="Casley Smith, J R" uniqKey="Casley Smith J" first="J. R." last="Casley-Smith">J. R. Casley-Smith</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">93-0640187</idno>
<date when="1993">1993</date>
<idno type="stanalyst">PASCAL 93-0640187 INIST</idno>
<idno type="RBID">Pascal:93-0640187</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D33</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000D75</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-a-pyrone (coumarin), and the effects of diethylcarbamazine (DEC)</title>
<author><name sortKey="Casley Smith, J R" sort="Casley Smith, J R" uniqKey="Casley Smith J" first="J. R." last="Casley-Smith">J. R. Casley-Smith</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Univ. Adelaide, Henry Thomas lab.</s1>
<s2>Adelaide SA 5001</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Jamal, S" sort="Jamal, S" uniqKey="Jamal S" first="S." last="Jamal">S. Jamal</name>
</author>
<author><name sortKey="Casley Smith, J R" sort="Casley Smith, J R" uniqKey="Casley Smith J" first="J. R." last="Casley-Smith">J. R. Casley-Smith</name>
</author>
</analytic>
<series><title level="j" type="main">Annals of tropical medicine and parasitology</title>
<title level="j" type="abbreviated">Ann. trop. med. parasitol.</title>
<idno type="ISSN">0003-4983</idno>
<imprint><date when="1993">1993</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of tropical medicine and parasitology</title>
<title level="j" type="abbreviated">Ann. trop. med. parasitol.</title>
<idno type="ISSN">0003-4983</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anthelmintic</term>
<term>Coumarine derivatives</term>
<term>Elephantiasis</term>
<term>Filariosis</term>
<term>Human</term>
<term>India</term>
<term>Lymphatic system</term>
<term>Lymphedema</term>
<term>Parasiticid</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lymphoedème</term>
<term>Eléphantiasis</term>
<term>Diéthylcarbamazine</term>
<term>Filariose</term>
<term>Système lymphatique</term>
<term>Antiparasitaire</term>
<term>Anthelminthique</term>
<term>Inde</term>
<term>Coumarine dérivé</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Inde</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Chronic filaritic lymphoedema and elephantiasis, in India, were treated orally with 5,6 benzo-a-pyrone (56 BaP; 1,2 benzo-a-pyrone; coumarin) in a double-blind, randomized, matched-group trial. Each group finally contained 40-55 patients. Patients were observed for about 2 years (ranging from 6 to 45 months, with 75% completing the 2 years). The 56 BaP slowly, but very significantly (P < 0.0001), reduced all grades of lymphoedema and elephantiasis. Two thirds of the oedema was lost by grade 2 over 2 years. Grades 3 to 5 were reduced by a fifth over that time. The greater the initial oedema, the greater was its rate of resolution</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0003-4983</s0>
</fA01>
<fA02 i1="01"><s0>ATMPA2</s0>
</fA02>
<fA03 i2="1"><s0>Ann. trop. med. parasitol.</s0>
</fA03>
<fA05><s2>87</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-a-pyrone (coumarin), and the effects of diethylcarbamazine (DEC)</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CASLEY-SMITH (J. R.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JAMAL (S.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CASLEY-SMITH (J. R.)</s1>
</fA11>
<fA14 i1="01"><s1>Univ. Adelaide, Henry Thomas lab.</s1>
<s2>Adelaide SA 5001</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA20><s1>247-258</s1>
</fA20>
<fA21><s1>1993</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>2075</s2>
<s5>354000035427770040</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>26 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>93-0640187</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Annals of tropical medicine and parasitology</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Chronic filaritic lymphoedema and elephantiasis, in India, were treated orally with 5,6 benzo-a-pyrone (56 BaP; 1,2 benzo-a-pyrone; coumarin) in a double-blind, randomized, matched-group trial. Each group finally contained 40-55 patients. Patients were observed for about 2 years (ranging from 6 to 45 months, with 75% completing the 2 years). The 56 BaP slowly, but very significantly (P < 0.0001), reduced all grades of lymphoedema and elephantiasis. Two thirds of the oedema was lost by grade 2 over 2 years. Grades 3 to 5 were reduced by a fifth over that time. The greater the initial oedema, the greater was its rate of resolution</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S06</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>235</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Eléphantiasis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Elephantiasis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Elefantiasis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Diéthylcarbamazine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Filariose</s0>
<s2>NM</s2>
<s2>L1</s2>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Filariosis</s0>
<s2>NM</s2>
<s2>L1</s2>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Filariosis</s0>
<s2>NM</s2>
<s2>L1</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Système lymphatique</s0>
<s2>L1</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Lymphatic system</s0>
<s2>L1</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema linfático</s0>
<s2>L1</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiparasitaire</s0>
<s5>18</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Parasiticid</s0>
<s5>18</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiparasitario</s0>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Anthelminthique</s0>
<s5>19</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Anthelmintic</s0>
<s5>19</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Antihelmíntico</s0>
<s5>19</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Inde</s0>
<s2>NG</s2>
<s5>44</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>India</s0>
<s2>NG</s2>
<s5>44</s5>
</fC03>
<fC03 i1="08" i2="X" l="GER"><s0>Indien</s0>
<s2>NG</s2>
<s5>44</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>India</s0>
<s2>NG</s2>
<s5>44</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Coumarine dérivé</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>94</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Coumarine derivatives</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>94</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>95</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>95</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>95</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Nématodose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nematod disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Nematodosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Helminthiase</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Helminthiasis</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Helmintiasis</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Asie</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="GER"><s0>Asien</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fN21><s1>328</s1>
</fN21>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000D75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PascalFrancis |étape= Curation |type= RBID |clé= Pascal:93-0640187 |texte= Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-a-pyrone (coumarin), and the effects of diethylcarbamazine (DEC) }}
This area was generated with Dilib version V0.6.31. |